Bruton tyrosine kinase (BTK) inhibitors are candidate therapies for COVID-19 as BTK is a critical mediator of B-cell receptor signaling and adaptive immunity and plays a key role in numerous immunologic signaling networks associated with innate immunity (eg, toll-like receptor [TLR] signaling).16 Here, BTK is linked to COVID-19.